Haleon plc (HLN)
Healthcare
- Fundamental
- 4
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore 2 is below the required floor of 3 and hard-blocks any long, with a second independent block from a 14.50% overnight gap (2026-10-28 regular close 10.00 -> 2026-10-29 regular open 8.55) that a US-hours stop cannot cover; neither entry type qualifies — no pullback limit (countertrend: price 8.775 < SMA50 9.51 with MACD -0.06 < 0, and below a declining SMA200 9.76 with no reclaim) and no breakout stop (a break of 8.79/8.80 runs straight into the 9.97-10.00 overhead gap and the chart scores only 2/5, below the 3 minimum).
Company overview
Haleon plc is a global consumer healthcare company involved in the research, development, production, and distribution of wellness products. Its product range includes oral care, pain management, respiratory health, and dietary supplements, with brands like Panadol, Voltaren, and Sensodyne. Established in 2021, Haleon is headquartered in Brentford, UK.
Fundamental
goodHaleon exhibits strong profitability and manageable leverage, with a reasonable valuation and solid financial health.
Haleon shows strong, defensive profitability (TTM gross margin ~64.77%, net margin ~15.11%) with manageable leverage (net debt/EBITDA ~2.59x) and healthy financial-strength indicators (Altman Z ~3.39). Multiples are mid-range (P/E ~19.90; EV/EBITDA ~14.20) while DCF outputs imply meaningful upside, but growth is modest and FX/regulatory risks remain. FundamentalScore: 4/5.
Sentiment
weakMedia sentiment is negative following a guidance cut and share price drop, with no positive retail or catalyst offsets.
Dominant driver is the 2026-10-29 Q3 trading update (earnings, announced via Reuters/FT/WSJ coverage): organic revenue growth of 2.6% came in below expectations and FY2026 organic revenue guidance was cut to roughly 2.5%, sending shares down ~14% to a 52-week low. Sentiment delta is determinately negative (baseline polarity_score ≈ -0.03 → scoring ≈ -0.21) and a moderate red-flag cap applies for sharp two-week deterioration with no offsetting market-rewarded bullish catalyst — the £500m buyback did not score as a bullish leg — while Reddit coverage is indeterminate.
Technical
weakThe stock is in a strong downtrend with no qualifying long setup, trading below all key averages.
Chart scores 2/5 — bounce-only, structurally broken. HLN trades at 8.775 below every key average (SMA20 9.62, SMA50 9.51, SMA200 9.76, EMA9 9.38, EMA21 9.52, WMA9 9.36, WMA21 9.64, DEMA14 9.35, TEMA14 9.11) after the 2026-10-29 Q3 guidance-cut gap (2026-10-28 regular close 10.00 -> 2026-10-29 regular open 8.55, -14.5%). ADX14 33.53 with price under the whole MA stack confirms a strong DOWN trend, not an emerging uptrend; MACD has rolled negative (line -0.06 below signal 0.09, histogram -0.15) and RSI14 35.77 / Williams %R -80.45 mark only a short-term oversold bounce attempt. No bullish confirmation across trend, momentum or volume, and technicalScore stays below the strategy's 3 minimum regardless of the qualitative block.
You’re looking at 2026-11-02 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

